RU2005129278A - Препаративные глюкокортикоиды для лечения патологического ангиогенеза глаз - Google Patents
Препаративные глюкокортикоиды для лечения патологического ангиогенеза глаз Download PDFInfo
- Publication number
- RU2005129278A RU2005129278A RU2005129278/14A RU2005129278A RU2005129278A RU 2005129278 A RU2005129278 A RU 2005129278A RU 2005129278/14 A RU2005129278/14 A RU 2005129278/14A RU 2005129278 A RU2005129278 A RU 2005129278A RU 2005129278 A RU2005129278 A RU 2005129278A
- Authority
- RU
- Russia
- Prior art keywords
- composition
- acetate
- concentration
- glucocorticoid
- fluoromethalone
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (16)
1. Способ лечения патологического ангиогенеза глаз и любого ассоциированного с ним отека, включающий введение композиции, содержащей эффективное количество глюкокортикоида и эффективное количество ацетата анекортава.
2. Способ по п.1, в котором глюкокортикоид выбран из группы, состоящей из ацетонида триамцинолона, преднизолона, ацетата преднизолона, римексолона, фторметалона, ацетата фторметалона и его фармацевтически приемлемых солей.
3. Способ по п.2, в котором глюкокортикоид представляет собой ацетонид триамцинолона.
4. Способ по п.3, в котором концентрация ацетонида триамцинолона в композиции составляет от 0,4 до 2,0% мас./об.
5. Способ по п.2, в котором глюкокортикоид представляет собой римексолон.
6. Способ по п.5, в котором концентрация римексолона в композиции составляет от 0,1 до 4,0% мас./об.
7. Способ по п.2, в котором глюкокортикоид представляет собой ацетат преднизолона.
8. Способ по п.7, в котором концентрация ацетата преднизолона в композиции составляет от 0,1 до 2,0% мас./об.
9. Способ по п.2, в котором глюкокортикоид представляет собой ацетат фторметалона.
10. Способ по п.9, в котором концентрация ацетата фторметалона в композиции составляет от 0,1 до 1,0% мас./об.
11. Способ по п.3, в котором концентрация ацетата анекортава в композиции составляет от 0,1 до 6% мас./об., а концентрация ацетонида триамцинолона в композиции составляет от 0,5 до 4,0% мас./об.
12. Способ по п.11, в котором концентрация ацетата анекортава в композиции составляет от 1 до 3% мас./об.
13. Способ по п.12, в котором концентрация ацетата анекортава в композиции составляет 3% мас./об.
14. Способ по п.1, в котором композицию доставляют с помощью инъекции в стекловидное тело, доставки в заднее юкстасклеральное пространство, субконъюнктивальной инъекции или через имплантированное устройство.
15. Способ по п.14, в котором композицию доставляют инъекцией в заднее юкстасклеральное пространство.
16. Способ по п.14, в котором композицию доставляют через имплантированное устройство.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44894403P | 2003-02-20 | 2003-02-20 | |
| US60/448,944 | 2003-02-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2005129278A true RU2005129278A (ru) | 2006-01-27 |
Family
ID=32908675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005129278/14A RU2005129278A (ru) | 2003-02-20 | 2004-02-05 | Препаративные глюкокортикоиды для лечения патологического ангиогенеза глаз |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20060074061A1 (ru) |
| EP (1) | EP1594511A2 (ru) |
| JP (2) | JP2006518383A (ru) |
| KR (1) | KR20050102653A (ru) |
| CN (1) | CN100431544C (ru) |
| AR (1) | AR043252A1 (ru) |
| AU (1) | AU2004212900A1 (ru) |
| BR (1) | BRPI0407742A (ru) |
| CA (1) | CA2516790A1 (ru) |
| MX (1) | MXPA05008396A (ru) |
| PL (1) | PL378209A1 (ru) |
| RU (1) | RU2005129278A (ru) |
| TW (1) | TW200507858A (ru) |
| UY (1) | UY28203A1 (ru) |
| WO (1) | WO2004073608A2 (ru) |
| ZA (1) | ZA200505990B (ru) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005032510A1 (en) * | 2003-09-23 | 2005-04-14 | Alcon, Inc. | Triamcinolone acetonide and anecortave acetate formulations for injection |
| US7257366B2 (en) * | 2003-11-26 | 2007-08-14 | Osmosis Llc | System and method for teaching a new language |
| EP1931387A4 (en) * | 2005-09-07 | 2012-07-11 | Southwest Res Inst | BIODEGRADABLE MICROTEILED PHARMACEUTICAL FORMULATIONS WITH IMPROVED RELEASE RATES |
| US9693967B2 (en) | 2005-09-07 | 2017-07-04 | Southwest Research Institute | Biodegradable microparticle pharmaceutical formulations exhibiting improved released rates |
| US20070149616A1 (en) * | 2005-12-22 | 2007-06-28 | Alcon Manufacturing, Ltd. | C3-Convertase Inhibitors for the Prevention and Treatment of Age-Related Macular Degeneration in Patients With At Risk Variants Of Complement Factor H |
| US20070173538A1 (en) * | 2005-12-23 | 2007-07-26 | Alcon, Inc. | PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE |
| GB0625844D0 (en) * | 2006-12-22 | 2007-02-07 | Daniolabs Ltd | The treatment of macular degeneration |
| CA2693888A1 (en) * | 2007-07-20 | 2009-01-29 | Alcon, Inc. | Pharmaceutical formulation for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye |
| JP6148175B2 (ja) * | 2010-05-10 | 2017-06-14 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 網膜中および／または網膜下における液体貯留の処置のための方法および組成物 |
| CA2951721C (en) * | 2014-06-12 | 2023-09-26 | The Research Foundation For The State University Of New York | Methods of using gap junctions as therapeutic targets for the treatment of degenerative disorders of the retina |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4975537A (en) * | 1985-10-23 | 1990-12-04 | The Upjohn Company | Δ9(11) -angiostatic steroids |
| US4686214A (en) * | 1985-10-30 | 1987-08-11 | Alcon Laboratories, Inc. | Anti-inflammatory compounds for ophthalmic use |
| US4771042A (en) * | 1985-11-25 | 1988-09-13 | The Upjohn Company | Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments |
| US4853224A (en) * | 1987-12-22 | 1989-08-01 | Visionex | Biodegradable ocular implants |
| US5371078A (en) * | 1988-10-31 | 1994-12-06 | Alcon Laboratories, Inc. | Angiostatic steroids and methods and compositions for controlling ocular hypertension |
| US5164188A (en) * | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
| US5378475A (en) * | 1991-02-21 | 1995-01-03 | University Of Kentucky Research Foundation | Sustained release drug delivery devices |
| US5770592A (en) * | 1991-11-22 | 1998-06-23 | Alcon Laboratories, Inc. | Prevention and treatment of ocular neovascularization using angiostatic steroids |
| US5556848A (en) * | 1993-12-27 | 1996-09-17 | Senju Pharmaceutical Co., Ltd. | Ophthalmic suspension containing diflupredonate |
| US5646136A (en) * | 1994-01-04 | 1997-07-08 | Duke University | Methods of inhibiting angiogenesis and tumor growth, and treating ophthalmologic conditions with angiostatic and therapeutic steroids |
| US5516522A (en) * | 1994-03-14 | 1996-05-14 | Board Of Supervisors Of Louisiana State University | Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same |
| US5869079A (en) * | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| US5773019A (en) * | 1995-09-27 | 1998-06-30 | The University Of Kentucky Research Foundation | Implantable controlled release device to deliver drugs directly to an internal portion of the body |
| US5736152A (en) * | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| US6011023A (en) * | 1997-08-27 | 2000-01-04 | Alcon Laboratories, Inc. | Angiostatic steroids |
| ES2231257T3 (es) * | 1999-10-21 | 2005-05-16 | Alcon Inc. | Dispositivo para la administracion de farmacos. |
| US6416777B1 (en) * | 1999-10-21 | 2002-07-09 | Alcon Universal Ltd. | Ophthalmic drug delivery device |
| MXPA02002376A (es) * | 1999-10-21 | 2002-08-28 | Alcon Universal Ltd | Entrega de droga al sub-tenon-. |
| US20060166956A1 (en) * | 2002-08-05 | 2006-07-27 | Jerdan Janice A | Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration |
-
2004
- 2004-02-05 WO PCT/US2004/003515 patent/WO2004073608A2/en active Application Filing
- 2004-02-05 US US10/545,053 patent/US20060074061A1/en not_active Abandoned
- 2004-02-05 RU RU2005129278/14A patent/RU2005129278A/ru not_active Application Discontinuation
- 2004-02-05 BR BRPI0407742-3A patent/BRPI0407742A/pt not_active IP Right Cessation
- 2004-02-05 MX MXPA05008396A patent/MXPA05008396A/es unknown
- 2004-02-05 CA CA002516790A patent/CA2516790A1/en not_active Abandoned
- 2004-02-05 KR KR1020057015189A patent/KR20050102653A/ko not_active Application Discontinuation
- 2004-02-05 CN CNB2004800043514A patent/CN100431544C/zh not_active Expired - Fee Related
- 2004-02-05 EP EP04708663A patent/EP1594511A2/en not_active Withdrawn
- 2004-02-05 ZA ZA200505990A patent/ZA200505990B/xx unknown
- 2004-02-05 US US10/772,963 patent/US20040167109A1/en not_active Abandoned
- 2004-02-05 PL PL378209A patent/PL378209A1/pl unknown
- 2004-02-05 JP JP2006503391A patent/JP2006518383A/ja active Pending
- 2004-02-05 AU AU2004212900A patent/AU2004212900A1/en not_active Abandoned
- 2004-02-19 UY UY28203A patent/UY28203A1/es not_active Application Discontinuation
- 2004-02-19 TW TW093104085A patent/TW200507858A/zh unknown
- 2004-02-20 AR ARP040100545A patent/AR043252A1/es not_active Application Discontinuation
-
2006
- 2006-12-01 JP JP2006326249A patent/JP2007056041A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AR043252A1 (es) | 2005-07-20 |
| AU2004212900A1 (en) | 2004-09-02 |
| EP1594511A2 (en) | 2005-11-16 |
| UY28203A1 (es) | 2004-08-31 |
| WO2004073608A3 (en) | 2005-03-24 |
| WO2004073608A2 (en) | 2004-09-02 |
| JP2006518383A (ja) | 2006-08-10 |
| US20060074061A1 (en) | 2006-04-06 |
| JP2007056041A (ja) | 2007-03-08 |
| ZA200505990B (en) | 2006-12-27 |
| MXPA05008396A (es) | 2006-03-30 |
| CN1750829A (zh) | 2006-03-22 |
| KR20050102653A (ko) | 2005-10-26 |
| BRPI0407742A (pt) | 2006-02-14 |
| TW200507858A (en) | 2005-03-01 |
| PL378209A1 (pl) | 2006-03-20 |
| CN100431544C (zh) | 2008-11-12 |
| CA2516790A1 (en) | 2004-09-02 |
| US20040167109A1 (en) | 2004-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6576650B1 (en) | Peripherally active anti-hyperalgesic opiates | |
| RU2008118889A (ru) | Спососб лечения первичных и вторичных форм глаукомы | |
| US6573282B1 (en) | Peripherally active anti-hyperalgesic opiates | |
| CA2502437A1 (en) | Method and composition containing latanoprost for treating ocular hypertension and glaucoma | |
| EA200200392A1 (ru) | Способ получения экстракта из растения рода trichocaulon или рода hoodia, экстракт, порошковый материал и композиция на его основе и их применение для производства медикамента для лечения, профилактики или преодоления ожирения и/или подавления аппетита | |
| DE60316779D1 (de) | Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen | |
| RU2004111596A (ru) | Офтальмические композиции в форме депо для периокулярного или субконъюнктивального введения | |
| JP2003505422A5 (ru) | ||
| RU2009148288A (ru) | Профилактическое или терапевтическое средство для возрастной дегенерации желтого пятна | |
| RU2005129278A (ru) | Препаративные глюкокортикоиды для лечения патологического ангиогенеза глаз | |
| WO2002009702A3 (en) | Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure | |
| RU2010110544A (ru) | Применение веществ для лечения потери зрения у людей с глаукомой и другими дегенеративными глазными заболеваниями | |
| Caccia | Clonazepam in facial neuralgia and cluster headache: clinical and electrophysiological study | |
| WO2005030221A1 (ja) | 加齢黄斑変性治療剤 | |
| BRPI0414699A (pt) | formulações de acetato de anecortave e acetonida de triancinolona para injeção | |
| ES2172415A1 (es) | Tratamiento del glaucoma y la hipertension ocular por medio de un analogo de la melatonina. | |
| US20180221343A1 (en) | Pharmaceutical composition for preventing or treating macular degeneration | |
| EP3190887B1 (en) | Methods for treating and preventing ocular diseases, disorders, and conditions with melanin | |
| ATE309796T1 (de) | Verfahren zur behandlung von augenerkrankungen | |
| JP2006518383A5 (ru) | ||
| WO1995034302A3 (en) | Method for reducing intraocular pressure in the mammalian eye by administration of calcium chelators | |
| LAVAL et al. | Role of cortisone in glaucoma surgery: Experimental results | |
| RU94046058A (ru) | Агент для лечения и профилактики катаракты, способ его получения, применение (+) - (2s, 3s)-3 (s)-3-метил-1-(3-метилбутилкарбомоил)бутилкарбамоил]-2-оксикарбоновой кислоты ее соли и ее этилового эфира для получения агента, способ лечения и профилактики катаракты, способ получения водного раствора | |
| RU2006101150A (ru) | Композиции нестероидных противовоспалительных средств для лечения патологического ангиогенеза глаз | |
| CA2442296A1 (en) | Therapeutic agents for retinochoroidal disorders comprising steroids as active ingredients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20080910 |